BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

290 related articles for article (PubMed ID: 15353489)

  • 1. Elevations in troponin I after percutaneous coronary interventions are associated with abnormal tissue-level perfusion in high-risk patients with non-ST-segment-elevation acute coronary syndromes.
    Bolognese L; Ducci K; Angioli P; Falsini G; Liistro F; Baldassarre S; Burali A
    Circulation; 2004 Sep; 110(12):1592-7. PubMed ID: 15353489
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Randomized comparison of upstream tirofiban versus downstream high bolus dose tirofiban or abciximab on tissue-level perfusion and troponin release in high-risk acute coronary syndromes treated with percutaneous coronary interventions: the EVEREST trial.
    Bolognese L; Falsini G; Liistro F; Angioli P; Ducci K; Taddei T; Tarducci R; Cosmi F; Baldassarre S; Burali A
    J Am Coll Cardiol; 2006 Feb; 47(3):522-8. PubMed ID: 16458130
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Abciximab in patients with acute coronary syndromes undergoing percutaneous coronary intervention after clopidogrel pretreatment: the ISAR-REACT 2 randomized trial.
    Kastrati A; Mehilli J; Neumann FJ; Dotzer F; ten Berg J; Bollwein H; Graf I; Ibrahim M; Pache J; Seyfarth M; Schühlen H; Dirschinger J; Berger PB; Schömig A;
    JAMA; 2006 Apr; 295(13):1531-8. PubMed ID: 16533938
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of tirofiban plus clopidogrel versus clopidogrel plus provisional abciximab on biomarkers of myocardial necrosis in patients with non-ST-elevation acute coronary syndromes treated with early aggressive approach. Results of the CLOpidogrel, upstream TIrofiban, in cath Lab Downstream Abciximab (CLOTILDA) study.
    Leoncini M; Toso A; Maioli M; Bellandi F; Badia T; Politi A; De Servi S; Dabizzi RP
    Am Heart J; 2005 Sep; 150(3):401. PubMed ID: 16169315
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Association between thrombolysis in myocardial infarction myocardial perfusion grade, biomarkers, and clinical outcomes among patients with moderate- to high-risk acute coronary syndromes: observations from the randomized trial to evaluate the relative PROTECTion against post-PCI microvascular dysfunction and post-PCI ischemia among antiplatelet and antithrombotic agents-Thrombolysis In Myocardial Infarction 30 (PROTECT-TIMI 30).
    Gibson CM; Kirtane AJ; Morrow DA; Palabrica TM; Murphy SA; Stone PH; Scirica BM; Jennings LK; Herrmann HC; Cohen DJ; McCabe CH; Braunwald E;
    Am Heart J; 2006 Oct; 152(4):756-61. PubMed ID: 16996854
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Elevations in troponin T and I are associated with abnormal tissue level perfusion: a TACTICS-TIMI 18 substudy. Treat Angina with Aggrastat and Determine Cost of Therapy with an Invasive or Conservative Strategy-Thrombolysis in Myocardial Infarction.
    Wong GC; Morrow DA; Murphy S; Kraimer N; Pai R; James D; Robertson DH; Demopoulos LA; DiBattiste P; Cannon CP; Gibson CM
    Circulation; 2002 Jul; 106(2):202-7. PubMed ID: 12105159
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of upstream tirofiban versus downstream tirofiban on myocardial damage and 180-day clinical outcomes in high-risk acute coronary syndromes patients undergoing percutaneous coronary interventions.
    Liu T; Xie Y; Zhou YJ; Li YP; Ma HY; Guo YH; Liu YY; Zhao YX; Shi DM
    Chin Med J (Engl); 2009 Aug; 122(15):1732-7. PubMed ID: 19781316
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treatment modalities of non-ST-elevation acute coronary syndromes in the real world. Results of the prospective R.OS.A.I.-2 registry.
    Registro Osservazionale Angina Instabile Investigators
    Ital Heart J; 2003 Nov; 4(11):782-90. PubMed ID: 14699708
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Preservation of myocardial microcirculation during mechanical reperfusion for myocardial ischemia with either abciximab or eptifibatide.
    Stoupakis G; Orlando J; Kalia H; Skurnick J; Saric M; Arora R
    J Invasive Cardiol; 2003 Sep; 15(9):476-80. PubMed ID: 12947204
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Achieved platelet aggregation inhibition after different antiplatelet regimens during percutaneous coronary intervention for ST-segment elevation myocardial infarction.
    Ernst NM; Suryapranata H; Miedema K; Slingerland RJ; Ottervanger JP; Hoorntje JC; Gosselink AT; Dambrink JH; de Boer MJ; Zijlstra F; van 't Hof AW
    J Am Coll Cardiol; 2004 Sep; 44(6):1187-93. PubMed ID: 15364318
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tissue characteristics of culprit lesion and myocardial tissue-level perfusion in non-ST-segment elevation acute coronary syndromes: The EARLY-MYO-ACS study.
    Yang G; Wang W; Sheng X; Yang F; Kong L; He J; Ding S; Shan P; Shang Y; Xiu J; Yang Y; Mintz GS; Pu J
    Int J Cardiol; 2019 Jul; 287():32-38. PubMed ID: 30772013
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impact of preprocedural TIMI flow on myocardial perfusion, distal embolization and mortality in patients with ST-segment elevation myocardial infarction treated by primary angioplasty and glycoprotein IIb/IIIa inhibitors.
    Maioli M; Zeymer U; van 't Hof AW; Gibson CM; Dudek D; Bellandi F; Noc M; Secco GG; Zorman S; Gabriel HM; Emre A; Cutlip D; Rakowski T; Gyongyosi M; Huber K; De Luca G;
    J Invasive Cardiol; 2012 Jul; 24(7):324-7. PubMed ID: 22781470
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Intracoronary versus intravenous administration of abciximab in patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention with thrombus aspiration: the comparison of intracoronary versus intravenous abciximab administration during emergency reperfusion of ST-segment elevation myocardial infarction (CICERO) trial.
    Gu YL; Kampinga MA; Wieringa WG; Fokkema ML; Nijsten MW; Hillege HL; van den Heuvel AF; Tan ES; Pundziute G; van der Werf R; Hoseyni Guyomi S; van der Horst IC; Zijlstra F; de Smet BJ
    Circulation; 2010 Dec; 122(25):2709-17. PubMed ID: 21098442
    [TBL] [Abstract][Full Text] [Related]  

  • 14. High post-treatment platelet reactivity is associated with a high incidence of myonecrosis after stenting for non-ST elevation acute coronary syndromes.
    Cuisset T; Frere C; Quilici J; Morange PE; Nait-Saidi L; Mielot C; Bali L; Lambert M; Alessi MC; Bonnet JL
    Thromb Haemost; 2007 Feb; 97(2):282-7. PubMed ID: 17264958
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Use of glycoprotein IIb/IIIa inhibitors in invasively-treated patients with non-ST elevation acute coronary syndrome.
    De Servi S; Mariani M; Vandoni P; Dellavalle A; Politi A; Poletti F; Bonizzoni E; Leoncinie M;
    J Cardiovasc Med (Hagerstown); 2006 Mar; 7(3):159-65. PubMed ID: 16645379
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [The clinical use of the GPIIb/IIIa inhibitors eptifibatide and tirofiban in the treatment of acute coronary syndromes of the "non-ST elevation" type].
    Galli M; Maggioni AP; Vassanelli C; Tavazzi L
    Ital Heart J Suppl; 2000 Feb; 1(2):202-11. PubMed ID: 10731377
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Increase in troponin levels after coronary angioplasty (PTCA) in stable angina pectoris].
    Varvarovský I; Brtko M; Branny M
    Vnitr Lek; 2004 Mar; 50(3):203-7. PubMed ID: 15125370
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Early administration of abciximab bolus in the emergency department improves angiographic outcome after primary PCI as assessed by TIMI frame count: results of the early ReoPro administration in myocardial infarction (ERAMI) trial.
    Gabriel HM; Oliveira JA; da Silva PC; da Costa JM; da Cunha JA
    Catheter Cardiovasc Interv; 2006 Aug; 68(2):218-24. PubMed ID: 16817177
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical benefits of adjunctive tirofiban therapy in patients with acute ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention.
    Shen J; Zhang Q; Zhang RY; Zhang JS; Hu J; Yang ZK; Zheng AF; Zhang X; Shen WF
    Coron Artery Dis; 2008 Jun; 19(4):271-7. PubMed ID: 18480672
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of early myocardial reperfusion and perfusion on myocardial necrosis/dysfunction and inflammation in patients with ST-segment and non-ST-segment elevation acute coronary syndrome: results from the PLATelet inhibition and patients Outcomes (PLATO) trial.
    Batra G; Renlund H; Kunadian V; James SK; Storey RF; Steg PG; Katus HA; Harrington RA; Gibson CM; Budaj A; Siegbahn A; Wallentin L
    Eur Heart J Acute Cardiovasc Care; 2022 Jun; 11(4):336-349. PubMed ID: 35213721
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.